Emily H.-Y. Cheng, M.D., Ph.D.

Emily Cheng
  • Assistant Professor
    • Department of Medicine
      • Oncology Division
        • Molecular Oncology Section
  • Research interests
    • Programmed cell death

Research

Our research focuses on dissecting the molecular mechanisms of programmed cell death. Apoptosis is essential for the successful development and maintenance of tissue homeostasis in all metazoans. Deregulation of apoptosis contributes to a variety of pathologic processes including cancer, neurodegenerative disorders, and autoimmune disease.

The BCL-2 family constitutes a crucial checkpoint in apoptosis and consists of both anti-apoptotic and pro-apoptotic members. Pro-apoptotic BCL-2 members can be further subdivided into more fully conserved, "multidomain" members or "BH3-only" members. Using genetic and biochemical approaches, we have helped delineate the core apoptotic pathway in mammals. The "BH3-only" molecules activate "multidomain" pro-apoptotic BAX and BAK to trigger a mitochondrion-dependent cell death pathway. Conversely, anti-apoptotic BCL-2/BCL-XL sequesters translocated "BH3-only" molecules in stable mitochondrial complexes, thus preventing the activation of BAX/BAK. Loss of function studies revealed that the absence of pro-apoptotic BAX and BAK creates a profound block in apoptosis triggered by diverse death signals. Thus, activation of a "multidomain" member, BAX or BAK, appears to be an essential gateway to the mitochondrion-mediated cell death program. However, how cells keep the potentially lethal BAX and BAK in check and how "BH3-only" molecules activate BAX and BAK remain unclear. Using protein cross-linking in conjunction with serial protein chromatographic purification steps, we have identified VDAC2 as a negative regulator of BAK activation.

We are currently investigating how "BH3-only" molecules integrate specific death signals to activate "multidomain" BAX/BAK and utilizing a proteomic approach to identify higher order multi-protein complexes at the mitochondrion that regulate apoptosis and mitochondrial homeostasis. Mouse genetic approaches are undertaken to probe the physiologic roles of death regulators in development. The apoptotic machinery is a promising target of cancer therapy since cancer cells often have a defect in the apoptotic pathway. Our ultimate goal is to apply the information obtained from studies of death regulators to develop novel anti-cancer therapeutics.

VDAC2-/- cells

Comparison of apoptotic hallmarks in VDAC2-/- and wt cells

Two-color fluorescence microscopy of wt and VDAC2-/- MEF lines at 4 hours after 1 µM STS. Red indicates cytochrome c and blue is Hoechst staining of DNA.

From: Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ
VDAC2 inhibits BAK activation and mitochondrial apoptosis.
Science 2003 Jul 25;301(5632):513-7

Biographical Sketch

Education

1990 MD, Taipei Medical College, Taiwan
1997 PhD (molecular biology), Johns Hopkins University, Baltimore, MD

Post-graduate Training

1991-1992 Resident in Pathology, Taipei Institute of Pathology, Taiwan
1992-1997 Graduate Student, Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
1997-1999 Resident in Anatomic Pathology, Barnes Hospital, Washington University School of Medicine, St. Louis, MO
1999-2000 Resident in Anatomic Pathology, Department of Pathology, Brigham & Women's Hospital, Boston, MA
1999-2003 Research Fellow, Dana-Farber Cancer Institute, Boston, MA

Academic Positions

2003-2004 Instructor, Department of Pathology, Harvard Medical School, Boston, MA
2004-present Assistant Professor, Departments of Medicine and Pathology & Immunology, Washington University, St. Louis, MO

Board Certification

2003 Anatomic Pathologist, American Board of Pathology

Honors & Awards

1986 Dr. Yeh Su Pathology Award
1989 First Annual Academic Award, Taipei Medical College
1990 Graduated second place in class, Taipei Medical College
1997 Twentieth Annual Young Investigator Award, Johns Hopkins University School of Medicine
1999-2002 Howard Hughes Medical Institute Postdoctoral Fellowship for Physicians
2003 Howard Temin Award, K01, NCI
2004 Edward Mallinckrodt Jr. Foundation
2005 Searle Scholars Program

Updated: April 29, 2008

Valid XHTML 1.0 Transitional